Must-read for patients: Dabrafenib/dabrafenib usage and dosage

Dabrafenib is considered a single agent for the treatment of people with BRAF V600E-mutated unresectable or metastatic melanoma. Dabrafenib combined with trametinib can treat BRAF V600E-positive unresectable or metastatic melanoma, metastatic non-small cell lung cancer, metastatic anaplastic thyroid cancer, unresectable or metastatic solid tumors, and low-grade glioma.

Before initiating treatment with dabrafenib as a single agent, the presence of the BRAF V600E mutation should be confirmed in the tumor sample; before starting the combination treatment with dabrafenib and trametinib, the presence of the BRAF V600E or V600K mutation should be confirmed in the tumor sample. Dabrafenib is available in capsule form and should be taken at least 1 hour before or 2 hours after a meal, or at the same time every day, approximately 12 hours apart. Swallow capsules whole; do not open, break or squeeze them.

The recommended dose of dabrafenib for adult patients is 150 mg orally twice daily; for pediatric patients weighing at least 26 kg, the recommended dose is based on body weight; for patients weighing 26-37 kg, the dose is 75 mg orally twice daily; for patients 38-50 kg, the dose is 100 mg orally twice daily; for patients weighing less than 26 kg, the recommended dose has not been determined.

If a patient develops intolerable adverse reactions after treatment with dabrafenib, the doctor may adjust the dose of the drug based on the severity of the condition, such as reducing, interrupting or stopping treatment. For adult patients treated with dabrafenib, if the recommended dose is 150 mg orally twice a day, the first dose can be reduced to 100 mg orally twice a day; the second dose can be reduced to 75 mg orally twice a day; the third dose can be reduced to 50 mg orally twice a day; if dabrafenib capsules 50 mg orally twice a day are not tolerated, please permanently discontinue treatment.